Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach

Campara, Maya; Shord, Stacy S.; Haaf, Christina

doi:10.1111/j.1365-2710.2008.00994.x

Cited by 42 publications

(35 citation statements)

References 17 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A dose of rasburicase costs several thousand dollars, which may not be affordable in LMIC even when the drug is available. Rasburicase at reduced doses (e.g., 0.1 mg/kg) may be given to reduce uric acid somewhat while simultaneously reducing costs [49][50][51]. Rasburicase is contraindicated in patients with known methemoglobinemia or G6PD deficiency.…”

Section: Managementmentioning

confidence: 97%

Supportive medical care for children with acute lymphoblastic leukemia in low- and middle-income countries

Ceppi

Antillón

Pacheco

et al. 2015

Expert Review of Hematology

View full text Add to dashboard Cite

In the last two decades, remarkable progress in the treatment of children with acute lymphoblastic leukemia has been achieved in many low- and middle-income countries (LMIC), but survival rates remain significantly lower than those in high-income countries. Inadequate supportive care and consequent excess mortality from toxicity are important causes of treatment failure for children with acute lymphoblastic leukemia in LMIC. This article summarizes practical supportive care recommendations for healthcare providers practicing in LMIC, starting with core approaches in oncology nursing care, management of tumor lysis syndrome and mediastinal masses, nutritional support, use of blood products for anemia and thrombocytopenia, and palliative care. Prevention and treatment of infectious diseases are described in a parallel paper.

show abstract

Section: Managementmentioning

confidence: 97%

Supportive medical care for children with acute lymphoblastic leukemia in low- and middle-income countries

Ceppi

Antillón

Pacheco

et al. 2015

Expert Review of Hematology

View full text Add to dashboard Cite

show abstract

“…However, a single infusion of 0.15 mg/kg has been reported to be effective, 11,12) thus we considered it important to perform theoretical evaluations of dose and regimen. We collected the data which are the serum concentration and uric acid level after administration of rasburicase for Japanese patients.…”

Section: Discussionmentioning

confidence: 99%

“…10) In Japan, rasburicase is normally administered intravenously once a day at a dose of 0.20 mg/kg for a maximum of 7 d based on clinical trials, though a single infusion of 0.15 mg/ kg was reported to be effective. 11,12) The package insert recommends that administration should be limited to the minimum time required, while taking into consideration inter-individual variability in efficacy. There have been no reports presented of theoretical analysis of the minimum required duration of administration, thus it is considered important to perform theoretical evaluations of dose, regimen, and the effects of rasburicase.…”

mentioning

confidence: 99%

Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model

Kimura

Kanehira

Takayanagi

et al. 2016

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Rasburicase has a strong and fast effect for reducing blood levels of uric acid. However, there have been no reports of theoretical analysis for the rational dose and interval of administration. Thus we constructed a pharmacokinetic and pharmacodynamic model to determine changes in uric acid level after rasburicase administration at various doses and regimens. The time courses of uric acid level predicted using our model were in good agreement with observed data, indicating adequate performance for our model. The therapeutic effects after a single infusion at various rates of generation of uric acid were predicted. The maximum effect was not a large difference, in spite of the generation rate. Then, the therapeutic effects of repeated administrations were predicted. The effect did not change when rasburicase was administered at more than the usual dose. Besides, as the administration interval increased, the difference between minimum and maximum level of uric acid became greater. However, in all doses and regimens, adequate therapeutic effects were obtained.In conclusion, the model was found useful for predicting therapeutic effect of rasburicase and individually determining rational dosage regimen of rasburicase.

show abstract

“…Rasburicase has proved effective in managing TLS [103][104][105], which usually occurs 48-72 h after initiation of cancer therapy when large numbers of tumor cells undergo apoptosis in a short time, releasing their intracellular contents into the circulation. This causes an ionic imbalance involving hyperkalemia and hyperphosphatemia, secondary hypercalcemia and hyperuricemia, and possibly acute kidney injury and death [106,107].…”

Section: Rasburicasementioning

confidence: 99%

Enzymes Approved for Human Therapy: Indications, Mechanisms and Adverse Effects

Baldo¹

2015

BioDrugs

View full text Add to dashboard Cite

Research and drug developments fostered under orphan drug product development programs have greatly assisted the introduction of efficient and safe enzyme-based therapies for a range of rare disorders. The introduction and regulatory approval of 20 different recombinant enzymes has enabled, often for the first time, effective enzyme-replacement therapy for some lysosomal storage disorders, including Gaucher (imiglucerase, taliglucerase, and velaglucerase), Fabry (agalsidase alfa and beta), and Pompe (alglucosidase alfa) diseases and mucopolysaccharidoses I (laronidase), II (idursulfase), IVA (elosulfase), and VI (galsulfase). Approved recombinant enzymes are also now used as therapy for myocardial infarction (alteplase, reteplase, and tenecteplase), cystic fibrosis (dornase alfa), chronic gout (pegloticase), tumor lysis syndrome (rasburicase), leukemia (L-asparaginase), some collagen-based disorders such as Dupuytren's contracture (collagenase), severe combined immunodeficiency disease (pegademase bovine), detoxification of methotrexate (glucarpidase), and vitreomacular adhesion (ocriplasmin). The development of these efficacious and safe enzyme-based therapies has occurred hand in hand with some remarkable advances in the preparation of the often specifically designed recombinant enzymes; the manufacturing expertise necessary for commercial production; our understanding of underlying mechanisms operative in the different diseases; and the mechanisms of action of the relevant recombinant enzymes. Together with information on these mechanisms, safety findings recorded so far on the various adverse events and problems of immunogenicity of the recombinant enzymes used for therapy are presented.

show abstract

Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach

Cited by 42 publications

References 17 publications

Supportive medical care for children with acute lymphoblastic leukemia in low- and middle-income countries

Supportive medical care for children with acute lymphoblastic leukemia in low- and middle-income countries

Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model

Enzymes Approved for Human Therapy: Indications, Mechanisms and Adverse Effects

Contact Info

Product

Resources

About